EBV framed in Burkitt lymphoma

Nature Medicine

Volumn 8, Issue 10, 2002, Pages 1086-1087

  Speck, Samuel H ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; MEMBRANE PROTEIN; VIRUS ANTIGEN;

B LYMPHOCYTE; BURKITT LYMPHOMA; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS LATENCY;

B-LYMPHOCYTES; BURKITT LYMPHOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; VIRUS LATENCY;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0036796086     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1002-1086     Document Type: Short Survey

References (13)

1. Crawford, D.H. Biology and disease associations of Epstein-Barr virus. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 461-473 (2001).
2. Kelly, G., Bell, A. & Rickinson, A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nature Med. 8, 1098-1104 (2002).
3. Thorley-Lawson, D.A. Epstein-Barr virus: Exploiting the immune system. Nature Rev. Immunol. 1, 75-82 (2001).
4. Yates, J.L., Warren, N. & Sugden, B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812-815 (1985).
5. Mosialos, G. et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389-399 (1995).
6. Zimber-Strobl, U. et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 15, 7070-7078 (1996).
7. Caldwell, R.G., Wilson, J.B., Anderson, S.J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405-411 (1998).
8. Babcock, G.J., Hochberg, D. & Thorley-Lawson, A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497-506 (2000).
9. Paulson, E.J. & Speck, S.H. Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J. Virol. 73, 9959-9968 (1999).
10. Staege, M.S. et al. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc. Natl. Acad. Sci. USA 99, 4550-4555 (2002).
11. Yoo, L.I. & Speck, S.H. Regulation of EBNA gene expression. Epstein-Barr Virus Report 7, 175-185 (2002).
12. Grossman, S.R., Johannsen, E., Tong, X., Yalamanchili, R. & Kieff, E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc. Natl. Acad. Sci. USA 91, 7568-7572 (1994).
13. Henkel, T., Ling, P.D., Hayward, S.D. & Peterson, M.G. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein Jκ. Science 265, 92-95 (1994).